Company identity
Company number 07386339
Company profile
UK company 07386339, incorporated on 23 September 2010.
The Native Antigen Company
Welcome to The Native Antigen Company. we are world-leading infectious disease reagents from the experts. Whether you need cutting edge reagents for your research or bulk products for manufacturing we can support all of your needs.
Company number 07386339
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
TM01 | Transaction MzUzNjI4MjY2N2FkaXF6a2N4
Published 31 Jul 2026 09:28
Company registered at Companies House
1 Jan 2017 to 30 Sep 2018
At the start of 2016, Zika virus hit the headlines with an outbreak in Brazil far larger than any seen before, causing a huge rise in the number of children born with smaller than average heads and other abnormalities. As this virus is relatively recent, there are very few diagnostic methods of detecting the disease it causes, and most of the currently av...
1 Mar 2016 to 28 Feb 2017
Diagnostic tests are a vital component of disease diagnosis and vaccine research. For any test, the important parameters are sensitivity (i.e. the ability of the test to correctly identify a positive sample) and specificity (i.e. its ability to discriminate correctly between different diseases). Most diagnostic tests are simple plate-based assays or pregn...
1 Aug 2014 to 31 Jul 2015
The global market for therapeutic monoclonal antibodies (mAbs) has become the fastest growing segment of the pharmaceutical industry. The antigen is the lynchpin of therapeutic mAb development, so understanding, controlling and engineering antigens to increase immunogenicity is of vital interest to the pharmaceutical and diagnostic industry. Despite the s...
1 Feb 2013 to 31 Jan 2014
The Native Antigen Company (NAC) proposes to examine the technical feasibility of developing a novel mammalian cell expression system which would overcome the current barriers to producing suitable antigens from enveloped viruses for use as vaccine candidates. Our innovative approach would centre on the provision of pure Virus-Like Particles (VLPs) contai...
1 Jan 2013 to 31 Mar 2014
Clostridium difficile infection (CDI) is a major cause of morbidity and mortality in economically developed countries. CDI is primarily linked with hospital admission and prior antimicrobial treatment. Although significant advances have been made to reduce incidence, a number of hypervirulent and highly transmissible strains have recently emerged. Resulta...
1 Mar 2012 to 28 Feb 2013
Early detection of infectious disease offers the greatest opportunity to contain potential outbreaks, save lives and decrease the economic burden of healthcare. Rapid diagnostic test kits are one of the most effective ways to achieve this, allowing health care workers or members of the public to identify disease in the community. These tests, usually in t...